Zinplava®
Provider Order Form Rev. 07/2023
Places for completed referral form & all required documents to (833) 786-0025



Please fax completed referral form & all req		EMOCRAPHICS			
Delicat Name		EMOGRAPHICS	Phone		
Patient Name:			Phone:		
Address:		,			
Allergies:		•		☐ in ☐ cm	
Patient Status: ☐ New to Therapy	☐ Dose or Frequency Chan	ge			
INSURANCE INFORMATION: Please attach copy of insurance card (front and back).					
	DIAC	GNOSIS*			
*ICD 10 Code	o Clostridium difficile, recurrent, A04	l.71			
Required	o Clostridium difficile, not specified a	as recurrent, A04.72			
INFUSION ORDERS					
MEDICATION DOSE		DIF	DIRECTIONS/DURATION		
Zinplava® (bezlotoxumab)	mg (10 mg/kg)	Infuse	IV over 60 minutes x 1 dose		
Has patient received therapy above from another facility?		lity Name:			
		t Treatment: Date of Next Treatment:			
PRE-MEDICATION ORDERS		LAB ORDERS			
☐ No premeds ordered at this time		Labs to be drawn by:	Infusion Center	nysician	
☐ Acetaminophen 650mg PO ☐ Diphenhydramine 25mg PO		☐ No labs ordered at this tir	me		
☐ Methylprednisolone 40mg IVP -OR- ☐ Hydrocortisone 100mg IVP		☐ Blood glucose q	□ CBC with diff/platelet q		
☐ Other:	,	□ CMP a			
		•			
		SICIAN INFORMATION			
Physician Signature:					
Physician Name:					
Address:					
Contact Person: Phone #: Fax #:					
Email Where Follow Up Documentation Should Be Sent:					
REQUIRED CLINICAL DOCUMENTATION					
Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.					
Clinical Information, select all that apply:					
 □ The patient has active C. difficile infection (CDI), e.g., frequent watery stool (≥3 per day), abdominal pain, fever, and/or nausea. □ Current CDI episode is confirmed with a positive stool test for C. difficile toxin. 					
Date stool sample collected:					
☐ The patient will be receiving standard of care antibacterial drug therapy for the treatment of CDI in conjunction with Zinplava®.					
Specify antibacterial therapy for cut					
Antibacterial therapy for CDI	Dose Route Frequ	uency Date Started	Anticipated Stop Date		
☐ Fidaxomicin (Dificid®)					
□ Vancomycin					
☐ Metronidazole			 		
	reconce. Sologically that combine				
☐ The patient is at high risk of CDI recu ☐ Age ≥65 years		e CDI at presentation (e.g., ZA	AR score ≥2)		
☐ History of CDI in the past 6 months ☐ Hypervirulent strain of <i>C. difficile</i> (ribotype 027, 078 or 244)					
☐ Immunocompromised state	•				
☐ Long-term use of systemic a					
 □ Patient has had prior episode(s) of CDI. • Number of previous CDI episode(s) within the last year: 					
Date(s) of previous CDI episode(s) within the last year:					
LAB AND TEST RESULTS (required)					
Positive <i>C. difficile</i> stool test					
PRIOR FAILED THERAPIES FOR CI			D (D)2		
Medication Failed:		tment:			
Medication Failed:	Dates of Treat	tment:	Reason for D/C:		